KR102527784B1 - 단백질 조정제로서 유용한 헤테로시클릭 아미드 - Google Patents

단백질 조정제로서 유용한 헤테로시클릭 아미드 Download PDF

Info

Publication number
KR102527784B1
KR102527784B1 KR1020187032396A KR20187032396A KR102527784B1 KR 102527784 B1 KR102527784 B1 KR 102527784B1 KR 1020187032396 A KR1020187032396 A KR 1020187032396A KR 20187032396 A KR20187032396 A KR 20187032396A KR 102527784 B1 KR102527784 B1 KR 102527784B1
Authority
KR
South Korea
Prior art keywords
alkyl
optionally substituted
alkoxy
amino
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187032396A
Other languages
English (en)
Korean (ko)
Other versions
KR20180124149A (ko
Inventor
애덤 케네스 찬리
마이클 지. 달시
제이슨 더블유. 도슨
샤오양 동
테리 브이. 휴즈
지안싱 강
라라 캐스린 레이스터
이첸 리안
유에 리
존 에프. 멜만
네이사 네빈스
조쉬 엠. 라만주루
조셉 제이. 로마노
그렌 제트. 왕
구오센 예
다오후아 장
Original Assignee
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 filed Critical 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드
Publication of KR20180124149A publication Critical patent/KR20180124149A/ko
Application granted granted Critical
Publication of KR102527784B1 publication Critical patent/KR102527784B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
  • Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
KR1020187032396A 2016-04-07 2017-04-05 단백질 조정제로서 유용한 헤테로시클릭 아미드 Active KR102527784B1 (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662319358P 2016-04-07 2016-04-07
US62/319,358 2016-04-07
US201762461301P 2017-02-21 2017-02-21
US62/461,301 2017-02-21
US201762461975P 2017-02-22 2017-02-22
US62/461,975 2017-02-22
KR1020187031915A KR102527786B1 (ko) 2016-04-07 2017-04-05 단백질 조정제로서 유용한 헤테로시클릭 아미드
PCT/IB2017/051945 WO2017175147A1 (en) 2016-04-07 2017-04-05 Heterocyclic amides useful as protein modulators

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187031915A Division KR102527786B1 (ko) 2016-04-07 2017-04-05 단백질 조정제로서 유용한 헤테로시클릭 아미드

Publications (2)

Publication Number Publication Date
KR20180124149A KR20180124149A (ko) 2018-11-20
KR102527784B1 true KR102527784B1 (ko) 2023-04-28

Family

ID=58503675

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187032396A Active KR102527784B1 (ko) 2016-04-07 2017-04-05 단백질 조정제로서 유용한 헤테로시클릭 아미드
KR1020187031915A Active KR102527786B1 (ko) 2016-04-07 2017-04-05 단백질 조정제로서 유용한 헤테로시클릭 아미드

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187031915A Active KR102527786B1 (ko) 2016-04-07 2017-04-05 단백질 조정제로서 유용한 헤테로시클릭 아미드

Country Status (33)

Country Link
US (4) US10981901B1 (enExample)
EP (2) EP3440076B1 (enExample)
JP (4) JP6746712B2 (enExample)
KR (2) KR102527784B1 (enExample)
CN (3) CN113549110B (enExample)
AU (4) AU2017247798C1 (enExample)
CA (1) CA3019630A1 (enExample)
CL (3) CL2018002850A1 (enExample)
CO (1) CO2018010727A2 (enExample)
CR (2) CR20200045A (enExample)
DK (1) DK3440076T3 (enExample)
DO (3) DOP2018000217A (enExample)
ES (1) ES2921855T3 (enExample)
HR (1) HRP20220936T1 (enExample)
HU (1) HUE058932T2 (enExample)
IL (4) IL285702B (enExample)
JO (1) JOP20170083B1 (enExample)
LT (1) LT3440076T (enExample)
MX (3) MX379169B (enExample)
MY (1) MY189100A (enExample)
NZ (1) NZ745957A (enExample)
PE (3) PE20181884A1 (enExample)
PH (3) PH12018502151B1 (enExample)
PL (1) PL3440076T3 (enExample)
PT (1) PT3440076T (enExample)
RS (1) RS63462B1 (enExample)
SG (3) SG11201808621TA (enExample)
SI (1) SI3440076T1 (enExample)
SM (1) SMT202200339T1 (enExample)
TW (3) TWI777014B (enExample)
UA (1) UA123407C2 (enExample)
UY (1) UY37195A (enExample)
WO (1) WO2017175147A1 (enExample)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
GEP20207182B (en) 2015-08-13 2020-11-25 Merck Sharp & Dohme Cyclic di-nucleotide compounds as sting agonists
CN114751950B (zh) 2016-03-18 2025-04-18 免疫传感器公司 环二核苷酸化合物及使用方法
JOP20170083B1 (ar) * 2016-04-07 2022-03-14 Glaxosmithkline Ip Dev Ltd أميدات هتيروسيكلية مفيدة كمعدلات بروتين
TN2020000158A1 (en) 2016-10-04 2022-04-04 Merck Sharp & Dohme BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
MX2019011655A (es) 2017-03-29 2019-12-19 Legochem Biosciences Inc Profarmaco de dimero de pirrolobenzodiazepina y compuesto conjugado ligando-conector de este.
CN118267470A (zh) 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
WO2018208667A1 (en) 2017-05-12 2018-11-15 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
JP2020529421A (ja) 2017-08-04 2020-10-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ
CA3071538A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. Benzo[b]thiophene sting agonists for cancer treatment
TW201927771A (zh) * 2017-10-05 2019-07-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 可作為蛋白質調節劑之雜環醯胺及其使用方法
WO2019069275A1 (en) * 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited STING AGONIST ADMINISTRATION METHODS
BR112020006780A2 (pt) 2017-10-05 2020-10-06 Glaxosmithkline Intellectual Property Development Limited moduladores do estimulador de genes do interferon (sting)
PE20210156A1 (es) 2017-11-10 2021-01-26 Takeda Pharmaceuticals Co Compuestos moduladores de sting y metodos de elaboracion y uso
US11685761B2 (en) 2017-12-20 2023-06-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
WO2019123340A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN110016021B (zh) * 2018-01-08 2021-05-07 成都先导药物开发股份有限公司 一种免疫调节剂
CN110016025B (zh) * 2018-01-08 2021-08-06 成都先导药物开发股份有限公司 一种免疫调节剂
EP3752150A1 (en) * 2018-02-16 2020-12-23 UCB Biopharma SRL Pharmaceutical 6,5 heterobicyclic ring derivatives
EP3768266A4 (en) * 2018-03-20 2021-12-22 Merck Sharp & Dohme Corp. OXO-TETRAHYDRO-ISOCHINOLINE-CARBOXYLIC ACIDS AS STING INHIBITORS
CN112118866A (zh) 2018-03-23 2020-12-22 科迪亚克生物科学公司 包含sting激动剂的细胞外囊泡
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
US10793557B2 (en) 2018-04-03 2020-10-06 Merck Sharp & Dohme Corp. Sting agonist compounds
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
MA52754A (fr) 2018-05-25 2021-04-14 Incyte Corp Composés hétérocycliques tricycliques en tant qu'activateurs de sting
CN112351778B (zh) * 2018-06-28 2023-04-04 江苏恒瑞医药股份有限公司 稠合三环杂环类化合物及其治疗用途
WO2020010451A1 (en) * 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
US10875872B2 (en) 2018-07-31 2020-12-29 Incyte Corporation Heteroaryl amide compounds as sting activators
AU2019326633B2 (en) 2018-08-24 2022-09-08 Adlai Nortye Biopharma Co., Ltd. High activity sting protein agonist
MA53438A (fr) 2018-08-24 2021-09-15 Codiak Biosciences Inc Vésicules extracellulaires ciblant des cellules dendritiques et utilisations associées
JP7166028B2 (ja) * 2018-08-29 2022-11-07 アドライ・ノーティ・バイオファーマ・カンパニー・リミテッド 高活性ｓｔｉｎｇタンパク質アゴニスト化合物
SMT202500141T1 (it) 2018-09-06 2025-05-12 Daiichi Sankyo Co Ltd Coniugati farmaco-anticorpo di derivati dinucleotidici ciclici
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
CN113329734A (zh) * 2018-12-06 2021-08-31 葛兰素史克知识产权开发有限公司 新颖的药物制剂
CN113195473B (zh) * 2018-12-14 2022-11-22 江苏恒瑞医药股份有限公司 三环化合物作为sting激动剂及其制备方法和医药用途
WO2020132566A1 (en) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Sting pyrazole agonists and uses thereof
WO2020132582A1 (en) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Sting agonists and uses thereof
US12129267B2 (en) 2019-01-07 2024-10-29 Incyte Corporation Heteroaryl amide compounds as sting activators
CN111471056B (zh) * 2019-01-23 2021-07-02 成都先导药物开发股份有限公司 一种大环类免疫调节剂
WO2020156363A1 (zh) * 2019-01-31 2020-08-06 成都先导药物开发股份有限公司 一种免疫调节剂
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CN113543851B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 2’3’-环二核苷酸及其前药
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
SG11202109702QA (en) 2019-03-21 2021-10-28 Codiak Biosciences Inc Extracellular vesicles for vaccine delivery
JP2022525924A (ja) 2019-03-21 2022-05-20 コディアック バイオサイエンシーズ， インコーポレイテッド 細胞外小胞コンジュゲート及びその使用
WO2020194160A1 (en) * 2019-03-28 2020-10-01 Lupin Limited Macrocyclic compounds as sting agonists
TW202104214A (zh) 2019-04-05 2021-02-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 化合物
WO2021000770A1 (zh) * 2019-07-02 2021-01-07 凯复制药有限公司 可增强免疫活性的杂环化合物、其制备方法及其在医药上的应用
US20220251200A1 (en) 2019-07-03 2022-08-11 Codiak Biosciences, Inc. Extracellular vesicles targeting t cells and uses thereof
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
MX420195B (es) * 2019-07-22 2025-02-10 Lupin Ltd Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
CN112279835B (zh) * 2019-07-24 2022-07-22 中国医学科学院药物研究所 芳环或芳杂环并咪唑类化合物，其制备方法及制药用途
CN114174285B (zh) * 2019-07-25 2023-10-31 上海济煜医药科技有限公司 杂环酰胺类化合物及其制备方法和应用
TW202114710A (zh) 2019-07-25 2021-04-16 英屬開曼群島商百濟神州有限公司 作為sting促效劑之環狀二核苷酸
US11155567B2 (en) * 2019-08-02 2021-10-26 Mersana Therapeutics, Inc. Sting agonist compounds and methods of use
CN112521371B (zh) * 2019-09-19 2022-11-25 中国药科大学 杂环酰胺类化合物、其可药用的盐及其制备方法和用途
CN112521394A (zh) * 2019-09-19 2021-03-19 中国药科大学 杂环酰胺类化合物、其可药用的盐及其制备方法和用途
EP4034150A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour
US20240099973A1 (en) 2019-09-25 2024-03-28 Lonza Sales Ag Extracellular vesicle compositions
EP4034276A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Methods of producing extracellular vesicles
US20230241089A1 (en) 2019-09-25 2023-08-03 Codiak Biosciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
CN114555602B (zh) * 2019-10-10 2024-02-06 百济神州有限公司 作为sting调节剂的杂环化合物
PE20221445A1 (es) 2019-10-16 2022-09-21 Chemocentryx Inc Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
WO2021083383A1 (zh) * 2019-11-02 2021-05-06 上海凌达生物医药有限公司 一类含氮稠环类sting调节剂类化合物、制备方法和用途
CN112940004B (zh) * 2019-12-11 2022-07-12 中国科学院上海药物研究所 一种杂环化合物及其用途
JP7662644B2 (ja) * 2019-12-18 2025-04-15 シーティーエックスティー・ピーティーワイ・リミテッド 化合物
CN113087668B (zh) * 2019-12-23 2022-11-04 中国科学院上海药物研究所 一类苯并咪唑二聚体、其制备方法及用途
CN113248475B (zh) * 2020-02-11 2023-03-17 中国科学院上海药物研究所 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
EP4115909A4 (en) 2020-03-06 2024-10-30 Daiichi Sankyo Company, Limited ANTIBODY-DRUG CONJUGATE WITH NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE
WO2021184017A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
AU2021236763A1 (en) 2020-03-20 2022-10-06 Lonza Sales Ag Extracellular vesicles for therapy
BR112022019919A2 (pt) * 2020-04-02 2023-02-14 Mersana Therapeutics Inc Conjugado de anticorpo-fármaco compreendendo agonistas de sting
EP4134098A4 (en) 2020-04-10 2024-05-15 ONO Pharmaceutical Co., Ltd. Method of cancer therapy
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
CN116940567A (zh) * 2020-09-02 2023-10-24 斯克里普斯研究学院 干扰素基因刺激物sting的激动剂
TW202227479A (zh) 2020-09-02 2022-07-16 日商第一三共股份有限公司 新穎內－β－Ｎ－乙醯葡萄糖胺苷酶
CA3192470A1 (en) 2020-09-23 2022-03-31 Tim SOOS Methods of producing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
EP4240488A1 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Antibody drug conjugates
JP2024503508A (ja) * 2021-01-15 2024-01-25 シージェン インコーポレイテッド 免疫調節性抗体－薬物コンジュゲート
CN112920172B (zh) * 2021-02-01 2022-03-22 厦门大学 一种干扰素刺激蛋白靶向化合物、其放射性标记物、及它们的制备方法与应用
WO2022177307A1 (ko) * 2021-02-17 2022-08-25 한국화학연구원 벤즈이미다졸 유도체를 유효 성분으로 포함하는 인터페론 유전자 자극제 조성물
KR102881036B1 (ko) * 2021-02-17 2025-11-05 한국화학연구원 벤즈이미다졸 유도체를 유효 성분으로 포함하는 인터페론 유전자 자극제 조성물
US20240423927A1 (en) 2021-04-20 2024-12-26 Institut Curie Compositions and methods for use in immunotherapy
WO2022246597A1 (en) * 2021-05-24 2022-12-01 Forever Millets Limited Imidazopyridine derivatives as sting agonists
US20240285755A1 (en) 2021-05-24 2024-08-29 Glaxosmithkline Biologicals Sa Adjuvants
AU2022300383A1 (en) * 2021-06-25 2024-01-18 Bolt Biotherapeutics, Inc. Bis-benzimidazole sting agonist immunoconjugates, and uses thereof
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023025256A1 (zh) * 2021-08-26 2023-03-02 成都先导药物开发股份有限公司 一种适合作为抗体偶联药物效应分子的sting激动剂
WO2023056468A1 (en) 2021-09-30 2023-04-06 Codiak Biosciences, Inc. Extracellular vesicle comprising cholesterol tagged sting-agonist
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
WO2023136589A1 (en) * 2022-01-11 2023-07-20 Bisichem Co., Ltd. Fused heteroaryl hydroxamates as sting agonists
EP4472739A1 (en) * 2022-02-02 2024-12-11 F. Hoffmann-La Roche AG Imidazole macrocycles for the treatment of autoimmune disease
KR20240150807A (ko) 2022-02-22 2024-10-16 아라리스 바이오테크 아게 2개 이상의 페이로드를 포함하는 펩티드 링커
KR20240155298A (ko) 2022-03-02 2024-10-28 다이이찌 산쿄 가부시키가이샤 Fc 함유 분자의 제조 방법
WO2024003773A1 (en) 2022-07-01 2024-01-04 Pfizer Inc. 2,7-naphthyridine compounds as mastl inhibitors
WO2024009191A1 (en) 2022-07-05 2024-01-11 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024048490A1 (ja) 2022-08-29 2024-03-07 第一三共株式会社 変異Ｆｃ領域を含む抗体薬物コンジュゲート
EP4598901A1 (en) * 2022-10-03 2025-08-13 Thomas Jefferson University Pyrrolidine and imidazolidine based dna polymerase theta inhibitors and use thereof
WO2024074977A1 (en) 2022-10-04 2024-04-11 Pfizer Inc. Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds
WO2024084364A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Compounds for the treatment of cancer
WO2024105563A1 (en) 2022-11-16 2024-05-23 Pfizer Inc. Substituted bicyclic pyridone derivatives
WO2024137619A1 (en) 2022-12-20 2024-06-27 Bolt Biotherapeutics, Inc. Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
WO2024180103A1 (en) 2023-02-27 2024-09-06 BioNTech SE Sting agonists containing benzylic alcohol and benzylic amine functional groups
WO2024182414A1 (en) 2023-02-27 2024-09-06 Biontech Us Inc. Sting agonists containing hydrazide, hydrazine, and hydroxamic acid functional groups
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
KR20250165440A (ko) 2023-04-05 2025-11-25 화이자 인코포레이티드 피리도[4,3-d]피리미딘 화합물
WO2024213979A1 (en) 2023-04-10 2024-10-17 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2025012195A1 (en) * 2023-07-10 2025-01-16 F. Hoffmann-La Roche Ag Bicyclic macrocycles for the treatment of autoimmune disease
US20250108048A1 (en) * 2023-07-31 2025-04-03 Sutro Biopharma, Inc. Sting agonist compounds and conjugates
KR20250040871A (ko) * 2023-09-15 2025-03-25 삼진제약주식회사 Sting(인터페론 유전자 자극인자) 활성화제로서의 헤테로 고리 유도체 및 이를 포함하는 약학적 조성물
EP4534147A1 (en) 2023-10-05 2025-04-09 Sulis Therapeutics ApS Sting antagonist compounds
WO2025094035A1 (en) 2023-11-01 2025-05-08 Pfizer Inc. Toll-like receptor agonists and conjugates thereof
EP4663632A1 (en) * 2024-06-13 2025-12-17 Sulis Therapeutics ApS Compounds useful for the modulation of the activity of sting
EP4663204A1 (en) 2024-06-13 2025-12-17 Sulis Therapeutics ApS Compounds useful for the modulation of the activity of sting

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027394A1 (en) 1998-11-05 2000-05-18 University College London Activators of soluble guanylate cyclase
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
JP2015525742A (ja) 2012-06-27 2015-09-07 ４エスツェー ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌、自己免疫性炎症及びｃｎｓ疾患の処置のためのビフルオロジオキサラン−アミノ−ベンゾイミダゾールキナーゼ阻害剤
WO2015185565A1 (en) 2014-06-04 2015-12-10 Glaxosmithkline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
CA2310896A1 (en) 1999-07-02 2001-01-02 Japan Tobacco Inc. Hcv polymerase suitable for crystal structure analysis and method for using the enzyme
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
CA2363274A1 (en) 1999-12-27 2001-07-05 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs for hepatitis c
CA2409221C (en) 2000-05-19 2010-10-26 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US7129219B2 (en) 2000-08-04 2006-10-31 Corixa Corporation Immunoeffector compounds
US6310224B1 (en) 2001-01-19 2001-10-30 Arco Chemical Technology, L.P. Epoxidation catalyst and process
SI1355916T1 (sl) 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
JPWO2002074769A1 (ja) 2001-03-19 2004-07-08 小野薬品工業株式会社 トリアザスピロ［５．５］ウンデカン誘導体を有効成分として含有する薬剤
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003007945A1 (en) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
EP1497469A4 (en) 2002-04-04 2005-06-08 Achillion Pharmaceuticals Inc TEST FOR ASSESSING THE ACTIVITY OF COMPOUNDS AGAINST HCV USING A NOVEL DETECTION SYSTEM IN THE HCV REPLICIC
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
WO2003106498A2 (en) 2002-06-13 2003-12-24 Crucell Holland, B.V. Agonistic binding molecules to the human ox40 receptor
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
WO2004037818A1 (en) 2002-10-24 2004-05-06 Glaxo Group Limited 1-acyl-pyrrolidine derivatives for the treatment of viral infections
BR0315937A (pt) 2002-11-01 2005-09-13 Viropharma Inc Composto, composição para a profilaxia ou tratamento de infecções virais, e, método para a profilaxia ou tratamento de infecções da hepatite c e doenças associadas com tais infecções em um hospedeiro vivo
WO2004055012A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Indane compounds as ccr5 antagonists
AU2003300911A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Heterocyclic compounds as ccr5 antagonists
EP1569647B1 (en) 2002-12-13 2008-08-20 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
ATE402176T1 (de) 2002-12-13 2008-08-15 Smithkline Beecham Corp Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
DE60318891T2 (de) 2002-12-13 2009-01-22 Smithkline Beecham Corp. Cyclopropylverbindungen als ccr5 antagonisten
CA2509711A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Piperidine derivatives as ccr5 antagonists
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2004072286A1 (ja) 2003-01-23 2004-08-26 Ono Pharmaceutical Co., Ltd. ヒトｐｄ−１に対し特異性を有する物質
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
ZA200600424B (en) 2003-08-01 2007-05-30 Genelabs Tech Inc Bicyclic imidazol derivatives against flaviviridae
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
US20050176792A1 (en) 2004-01-14 2005-08-11 Boehringer Ingelheim Pharmaceuticals, Inc. Ketone substituted benzimidazole compounds
EP1711495A2 (en) 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
PL1718608T3 (pl) 2004-02-20 2013-11-29 Boehringer Ingelheim Int Inhibitory polimerazy wirusowej
EP1740192B1 (en) 2004-03-15 2012-06-13 David K. R. Karaolis Cyclic dinucleotide for stimulating the immune of inflammatory response
WO2005105761A1 (en) 2004-04-28 2005-11-10 Arrow Therapeutics Limited Morpholinylanilinoquinazo- line derivatives for use as antiviral agents
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
PL1781662T3 (pl) 2004-08-18 2011-08-31 Pfizer Inhibitory zależnej od RNA polimerazy RNA wirusa zapalenia wątroby typu C, i kompozycje i terapie wykorzystujące je
GB0423673D0 (en) 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
US20070060589A1 (en) * 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
JP2008540370A (ja) 2005-05-04 2008-11-20 エフ．ホフマン−ラ ロシュ アーゲー ヘテロ環式抗ウイルス化合物
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CA2607617A1 (en) 2005-05-09 2006-11-16 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
BR122020016659B8 (pt) 2005-05-10 2021-07-27 Incyte Holdings Corp moduladores de 2,3-dioxigenase de indolamina e métodos de modulação de atividade de inibição e de imunossupressão
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2703011A3 (en) 2007-05-07 2014-03-26 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
EP2242771B1 (en) 2007-12-14 2013-07-17 Bristol-Myers Squibb Company Binding molecules to the human ox40 receptor
MY150596A (en) 2008-02-01 2014-01-30 Takeda Pharmaceutical Hsp90 inhibitors
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP2805939B1 (en) * 2008-05-19 2018-06-27 Merck Sharp & Dohme Corp. Heterocyclic compounds as factor IXA inhibitors.
MX2011002250A (es) 2008-08-25 2011-08-17 Amplimmune Inc Antagonistas de muerte celular programada-1 y métodos de uso de los mismos.
MX2011003195A (es) 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
CN102438652B (zh) 2008-11-12 2014-08-13 米迪缪尼有限公司 抗体制剂
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
MX2011010132A (es) 2009-03-27 2011-10-14 Presidio Pharmaceuticals Inc Inhibidores de anillo fusionado de hepatitis c.
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UY33288A (es) * 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
CA2794153C (en) * 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
EP2571878B1 (en) * 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
CN101898945B (zh) 2010-07-27 2013-05-08 大连理工大学 盐析萃取发酵液中丙酮和丁醇的方法
PE20180042A1 (es) 2010-08-23 2018-01-09 Univ Texas Anticuerpos anti-ox40 y metodos de uso de los mismos
EP2651926A4 (en) * 2010-12-15 2014-07-09 Abbvie Inc ANTI-VIRAL COMPOUNDS
SG193428A1 (en) 2011-03-31 2013-10-30 Inst Nat Sante Rech Med Antibodies directed against icos and uses thereof
MY193562A (en) 2011-08-01 2022-10-19 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
JP6038920B2 (ja) 2011-08-23 2016-12-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗ｏｘ４０抗体およびそれを使用する方法
KR20150004416A (ko) 2012-04-30 2015-01-12 글렌 엔. 바버 면역 반응의 조절
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
WO2013185052A1 (en) 2012-06-08 2013-12-12 Aduro Biotech Compostions and methods for cancer immunotherapy
ES2684552T3 (es) 2012-09-03 2018-10-03 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos dirigidos contra ICOS para tratar la enfermedad de injerto contra hospedador
CN107892719B (zh) 2012-10-04 2022-01-14 达纳－法伯癌症研究所公司 人单克隆抗-pd-l1抗体和使用方法
EA201590396A1 (ru) 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
RS59500B1 (sr) 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用
CN106460057A (zh) 2014-06-02 2017-02-22 贝斯4创新公司 核苷酸多态性检测方法
BR112017000497B1 (pt) 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
AU2016235362B2 (en) 2015-03-23 2021-12-16 Jounce Therapeutics, Inc. Antibodies to ICOS
GEP20207182B (en) 2015-08-13 2020-11-25 Merck Sharp & Dohme Cyclic di-nucleotide compounds as sting agonists
MX363780B (es) 2015-12-03 2019-04-03 Glaxosmithkline Ip Dev Ltd Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón.
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
JOP20170083B1 (ar) * 2016-04-07 2022-03-14 Glaxosmithkline Ip Dev Ltd أميدات هتيروسيكلية مفيدة كمعدلات بروتين

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027394A1 (en) 1998-11-05 2000-05-18 University College London Activators of soluble guanylate cyclase
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
JP2015525742A (ja) 2012-06-27 2015-09-07 ４エスツェー ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌、自己免疫性炎症及びｃｎｓ疾患の処置のためのビフルオロジオキサラン−アミノ−ベンゾイミダゾールキナーゼ阻害剤
WO2015185565A1 (en) 2014-06-04 2015-12-10 Glaxosmithkline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting

Also Published As

Publication number Publication date
EP3440076A1 (en) 2019-02-13
AU2017247798A1 (en) 2018-09-27
PE20181920A1 (es) 2018-12-11
JP6746712B2 (ja) 2020-08-26
CA3019630A1 (en) 2017-10-12
MX2020009947A (es) 2021-10-26
CL2018003290A1 (es) 2019-02-01
AU2018229497B2 (en) 2019-06-27
CR20200044A (es) 2020-03-11
AU2017247798B2 (en) 2019-10-31
BR122018070836A2 (pt) 2019-09-10
BR122018070838A8 (pt) 2022-07-19
IL295649B2 (en) 2025-12-01
UA123407C2 (uk) 2021-03-31
TWI776806B (zh) 2022-09-11
ES2921855T3 (es) 2022-09-01
IL261657B (en) 2021-09-30
JOP20170083B1 (ar) 2022-03-14
CN109071514A (zh) 2018-12-21
AU2017247798C1 (en) 2020-08-27
AU2018229498A1 (en) 2018-10-04
MX387353B (es) 2025-03-18
KR20180132806A (ko) 2018-12-12
RS63462B1 (sr) 2022-08-31
US11970480B2 (en) 2024-04-30
PT3440076T (pt) 2022-07-29
IL261482A (en) 2018-10-31
CR20200045A (es) 2020-03-11
WO2017175147A1 (en) 2017-10-12
UY37195A (es) 2017-10-31
SI3440076T1 (sl) 2022-09-30
DK3440076T3 (da) 2022-07-11
EP4032885A1 (en) 2022-07-27
AU2020200692C1 (en) 2021-03-04
TWI868471B (zh) 2025-01-01
SG10201900629VA (en) 2019-02-27
HRP20220936T1 (hr) 2022-10-28
MX2020009948A (es) 2021-10-26
US10189820B2 (en) 2019-01-29
IL295649A (en) 2022-10-01
TW202246285A (zh) 2022-12-01
JP2021105013A (ja) 2021-07-26
JP7119158B2 (ja) 2022-08-16
IL261657A (en) 2018-10-31
US20210139473A1 (en) 2021-05-13
SG10201900628RA (en) 2019-02-27
MY189100A (en) 2022-01-25
SG11201808621TA (en) 2018-10-30
PE20181884A1 (es) 2018-12-07
PH12018502151B1 (en) 2022-01-12
AU2018229497A1 (en) 2018-10-04
JP2020100646A (ja) 2020-07-02
CN109608443B (zh) 2021-09-07
JP6861307B2 (ja) 2021-04-21
DOP2020000019A (es) 2020-03-15
US20230071675A1 (en) 2023-03-09
US20180105514A1 (en) 2018-04-19
BR122018070836A8 (pt) 2022-07-19
MX379169B (es) 2025-03-10
PH12018502202A1 (en) 2020-06-22
US10981901B1 (en) 2021-04-20
KR102527786B1 (ko) 2023-04-28
JP2022166060A (ja) 2022-11-01
CN109608443A (zh) 2019-04-12
KR20180124149A (ko) 2018-11-20
MX2018012333A (es) 2019-03-07
CO2018010727A2 (es) 2018-10-22
SMT202200339T1 (it) 2022-09-14
NZ750114A (en) 2025-05-30
PL3440076T3 (pl) 2022-09-05
DOP2020000018A (es) 2020-03-15
IL261482B (en) 2021-09-30
AU2020200692B2 (en) 2020-08-27
CN113549110A (zh) 2021-10-26
TW201920161A (zh) 2019-06-01
EP3440076B1 (en) 2022-06-01
AU2018229497C1 (en) 2020-09-03
BR112018070655A2 (pt) 2019-02-05
TW201738235A (zh) 2017-11-01
PE20181919A1 (es) 2018-12-11
MX387354B (es) 2025-03-18
IL285702B (en) 2022-09-01
US11365190B2 (en) 2022-06-21
CN109071514B (zh) 2021-07-06
AU2018229498B2 (en) 2019-06-27
PH12018502151A1 (en) 2019-07-08
CN113549110B (zh) 2024-08-16
BR122018070838A2 (pt) 2019-09-10
HUE058932T2 (hu) 2022-09-28
IL295649B1 (en) 2025-08-01
TWI777014B (zh) 2022-09-11
AU2020200692A1 (en) 2020-02-20
JP7466596B2 (ja) 2024-04-12
AU2018229498C1 (en) 2020-09-03
CL2018003291A1 (es) 2019-02-01
LT3440076T (lt) 2022-09-26
NZ745957A (en) 2020-07-31
DOP2018000217A (es) 2018-10-31
IL285702A (en) 2021-09-30
PH12018502179A1 (en) 2020-06-15
CL2018002850A1 (es) 2018-12-14
JP2019510796A (ja) 2019-04-18

Similar Documents

Publication Publication Date Title
US11970480B2 (en) Heterocyclic amides useful as protein modulators
EP3692033A1 (en) Modulators of stimulator of interferon genes (sting) useful in treating hiv
CN111417630A (zh) 干扰素基因刺激因子(sting)的调节剂
EA037671B1 (ru) Гетероциклические амиды, пригодные в качестве модуляторов белков
HK40069191A (en) Heterocyclic amides useful as protein modulators
HK1259737B (en) Heterocyclic amides useful as protein modulators
HK1259737A1 (en) Heterocyclic amides useful as protein modulators
BR122018070836B1 (pt) Compostos de amidas heterocíclicas moduladoras de sting, composição contendo ditos compostos e uso dos mesmos para tratar uma doença mediada por sting

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20181108

Application number text: 1020187031915

Filing date: 20181102

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200406

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211129

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220711

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230206

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230426

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230426

End annual number: 3

Start annual number: 1

PG1601 Publication of registration